Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 291

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 291
---
 in estimate for product returns.When we perform services under our agreement with the DoD, we recognize product revenue and a corresponding contract asset as our right to consideration is conditioned on something other than the passage of time. See Note 6 for further discussion. The following table summarizes balances and activities in our contract asset account (in thousands): Balance atBeginningof PeriodAdditionsSubtractions Balanceat End ofPeriodNine months ended September 30, 2025Contract asset, included in other current assets (1)$351 $10,903 $(8,178)$3,076 Contract asset, included in other assets (long term) (2)$71,307 $— $(10,970)$60,337 (1)The $3.1 million contract asset is derived from our agreement with the DoD.(2)The Clover contract asset was included in non-current assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. During the nine months ended September 30, 2025, we recorded an allowance for doubtful accounts of approximately $11.0 million relating to the contract asset recognized for Clover. See Note 6 for further discussion.

10. Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of our common stock outstanding.For the calculation of diluted net income per share, net income for basic net income per share is adjusted by the effect of dilutive securities, including awards under our equity compensation plans. Diluted net income per share is computed by dividing the resulting net income by the weighted-average number of fully diluted common shares outstanding.

21

The numerators and denominators of the basic net income (loss) and diluted net income per share computations for our common stock are calculated as follows (in thousands): Three Months EndedSeptember 30,Nine Months EndedSeptember 30, 2025202420252024NumeratorNet income (loss), basic$26,927 $17,594 $(50,451)$20,259   Add: interest expense on convertible notes$1,231 $1,274 $— $— Net income (loss), diluted$28,158 $18,868 $(50,451)$20,259 DenominatorWeighted average common stock outstanding, basic117,307 131,133 120,471 130,746 Effect of dilutive